7th Annual Individualized & Precision Medicine Conference to be held in Baltimore from Oct.

This conference brings together multiple stakeholders, including payers, molecular diagnostics businesses, genome analysis/interpretation companies, clinicians and many more in order to provide attendees with a holistic view of the precision medication landscape. Key topics as of this season's Conference include: – Finding worth in pharmacogenomics – The task of adopting NGS panels – Making RNA sequencing actionable in the clinic – Integration of entire genome sequencing into clinical medication – Precision healthcare platforms – Balancing public and personal intellectual property passions in a post Mayo-Myriad age – Precision medicine and plan in the making Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Good Begin GeneticsAmbry Genetics presents groundbreaking TP53 gene data at ASHG; TP53 linked to breast cancerApplying a top restaurant model to health care communications: an interview with Brandi Robinson, SanofiFeatured Audio speakers consist of: Robert Green, MD, FACP, Director of Applied Genomics Study Informatics, Director, Health Heritage Family HEALTH BACKGROUND Project, Middle for Biomedical Research Informatics at NorthShore University Analysis Institute Gitte Pederson, CEO at Genomic Expression Anya Schiess, MBA, General Partner and Co-Founder at Healthy Ventures Paul Sheives, JD, Vice President, Reimbursement & Regulatory Plan at American Clinical Laboratory Association Elaine Cheung, Director of Strategic Partnerships at Illumina Angela Davies, MD, FRCP , Chief Medical Officer at Champions Oncology Mark Gerstein, Ph.D., Professor of Biomedical Informatics at Yale University Laura Lyman Rodriquez, Ph.D., Director, Office of Policy, Communications and Education at National Human being Genome Analysis Institute Jen Madsen, MPH, Health Policy Advisor at Arnold & Porter Ken Ramos, MD, Ph.D., PharmB, Associate Vice President for Precision Health Sciences, Professor of Medication at Arizona Health Sciences Center Birgit Reitmaier, Ph.D., Head of Technology & Biomarkers, Global Licensing & Business Development at Merck Serono division, Merck KGaA..Related StoriesNew Cleveland Clinic research shows bariatric surgery is safe choice for managing type 2 diabetes in over weight or mildly obese patientsBetalin launches brand-new EMP technology that could transform diabetes treatmentWeight-loss medical procedures may be safe for managing type 2 diabetes in sufferers with gentle obesityIn ACCORD Lipid, fenofibrate decreased micro – and macro-albuminuria, markers of diabetic renal disease. That is consistent with results from previous clinical trials.